| Description | Fosmanogepix (APX001) is a first-in-class, orally available broad-spectrum antifungal agent. It acts as an N-phosphonooxymethyl prodrug that undergoes rapid and complete metabolism by systemic alkaline phosphatases. This metabolism leads to the formation of the active moiety, APX001A. Fosmanogepix (APX001), with its ability to target the highly conserved Gwt1 fungal enzyme, holds great potential for the development of treatments against invasive fungal infections. |
| Synonyms | APX001, E1211 |
| molecular weight | 468.4 |
| Molecular formula | C22H21N4O6P |
| CAS | 2091769-17-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 5 mg/mL (10.67 mM), when pH is adjusted to 4 with HCl. Sonication is recommended. |
| References | 1. Shaw KJ, et al. In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00523-18. 2. Gebremariam T, et al. APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01713-18. |